Study details
Enrolling now
A Phase 1 Trial of WVE-007
Wave Life Sciences Ltd.
NCT IDNCT06842186ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
136
Study length
about 1.7 years
Ages
18–60
Locations
1 site in MD
What this study is about
Researchers are testing the safety and how your body processes WVE-007 when given as a medication under the skin. The trial will last for about two years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take WVE-007
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: The proportion of participants with adverse events
Secondary: Maximum concentration of WVE-007 in plasma (Cmax)